Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Pujol

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Nature Genetics|October 7, 2008
Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumorRichard H Scott, Jenny Douglas, Linda Baskcomb, et al.
Breast Cancer Research and Treatment|August 6, 2017
Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European womenCarole Corsini, Sarra Henouda, Dalel Ben Nejima, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study)Pascal Pujol, Lise Roca, Alain Lortholary, et al.
The New England Journal of Medicine|June 7, 2011
Exemestane for breast-cancer prevention in postmenopausal womenPaul E Goss, James N Ingle, José E Alés-Martínez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal CancerAlexandre Prieur, Monica Cappellini, Guillaume Habif, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsStanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
Familial Cancer|November 15, 2011
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trialPascal Pujol, Christine Lasset, Pascaline Berthet, et al.
Breast Cancer Research and Treatment|November 14, 2015
Mutation analysis of PALB2 gene in French breast cancer familiesFrancesca Damiola, Inès Schultz, Laure Barjhoux, et al.
Breast Cancer Research : BCR|July 6, 2012
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Nature Genetics|October 7, 2008
Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumorRichard H Scott, Jenny Douglas, Linda Baskcomb, et al.
Breast Cancer Research and Treatment|August 6, 2017
Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European womenCarole Corsini, Sarra Henouda, Dalel Ben Nejima, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2025
Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study)Pascal Pujol, Lise Roca, Alain Lortholary, et al.
The New England Journal of Medicine|June 7, 2011
Exemestane for breast-cancer prevention in postmenopausal womenPaul E Goss, James N Ingle, José E Alés-Martínez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal CancerAlexandre Prieur, Monica Cappellini, Guillaume Habif, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsStanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
Familial Cancer|November 15, 2011
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trialPascal Pujol, Christine Lasset, Pascaline Berthet, et al.
Breast Cancer Research and Treatment|November 14, 2015
Mutation analysis of PALB2 gene in French breast cancer familiesFrancesca Damiola, Inès Schultz, Laure Barjhoux, et al.
Breast Cancer Research : BCR|July 6, 2012
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Pageof 10